Condition
Carcinoma, Non-Small-Cell Lung|Mesothelioma
Estimated Enrollment: 18
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: CLBH589B2109
Study First Received: September 26, 2007
Last Updated: November 26, 2012
Estimated Primary Completion Date: January 2009
Primary Outcome Measures:
Pharmacokinetic (PK) parameters|Response rate assessed by comparing tumor size via radiology scans (CTs or MRIs)|Safety (until disease progression, unacceptable toxicity or study completion) assessed by duration of patient participation|Tolerability (until disease progression, unacceptable toxicity or study completion) assessed by duration of patient participation
Sponsors and Collaborators:
Novartis Pharmaceuticals|Novartis
Website Link: https://ClinicalTrials.gov/show/NCT00535951
